Download NanoAntilatHIV: Development of a new drug/nucleic acid

NanoAntilatHIV: Development of a new
drug/nucleic acid nanocarrier against HIV-1 latency
ADRESSED PATHOLOGY:
HIV-1 Infection
GENERAL OBJECTIVES:
Development of a new therapeutic strategy against HIV-1 infection which avoids the toxicity
and resistances of the actual drugs (antiretrovirals). This new approach reduces the size of
the latent reservoirs of human immunodeficiency virus type 1 (HIV-1) in infected cells by
means the design of a novel nanosystem able to act in a combined therapy based on the
codelivery of drugs and nucleic acids into the infected cells.
PARTICIPANTS:
—
—
—
—
Blanca González/María Vallet, GIBI-UCM, Universidad Complutense de Madrid.
Francisco Javier de la Mata, GDAB-UAH, Universidad de Alcalá de Henares.
María Ángeles Muñoz,
Muñoz LIBM-HGUGM,
LIBM-HGUGM Hospital General Universitario Gregorio Marañón.
Marañón
Ramón Eritja, GQNA-CSIC, Instituto de Química Avanzada de Cataluña.